Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Sin, D. Tashkin, F. Radner, U. Sjobring, A. Thoren, P. Calverley, S. Rennard (Vancouver, Canada; Los Angeles, Omaha, United States Of America; Molndal, Sweden; Liverpool, United Kingdom). Risk of pneumonia related to budesonide use in COPD: An updated pooled analysis. Eur Respir J 2012; 40: Suppl. 56, 2117

Member's Comments

No comment yet.

Related content which might interest you: A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Prevalence of COPD: updated meta-analysis results Source: Annual Congress 2007 - Environmental and clinical aspects of COPD Year: 2007 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Clinical and demographic factors associated with pneumonia risk in a COPD patient cohort Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Chronic NIV in COPD: an exploration of pooled individual patient data Source: Virtual Congress 2021 – Home mechanical ventilation: organisation and outcomes Year: 2021 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 COPD subtypes at greatest risk of pneumonia: Cluster analysis Source: Annual Congress 2013 –Factors associated with outcomes in COPD Year: 2013 Prediction models for exacerbations in different COPD patient populations: Results of five large databases Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD Year: 2016 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Risk of pneumonia in chronic obstructive pulmonary disease patients treated with inhaled corticosteroids. Results from the OUTPUL study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 COPD exacerbation admissions: Analysis of demographics and mortality Source: Annual Congress 2013 –COPD treatment Year: 2013 Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Tiotropium use in COPD: association with clinical diagnosis assignment Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007